Mesenchymal Stem Cell-Derived Exosomes: Toward Cell-Free Therapeutic Strategies in Chronic Kidney Disease

Cao, Qinghua; Huang, Chunling; Chen, Xinming; Pollock, Carol

doi:10.3389/fmed.2022.816656

Cited by 20 publications

(22 citation statements)

References 138 publications

(165 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent studies have also confirmed that MSCs alleviate other animal models of AKI induced by ischemia–reperfusion, glycerol, sepsis, cecal ligation and puncture 162 , 163 , and so on. In addition, MSCs transplantation significantly alleviated CKD progression by inhibiting renal tubular epithelial cell apoptosis, EMT process, and inducing cell autophagy 15 , 164 . For example, Liu et al 165 showed that treatment with BMMSCs restricted inflammation and renal damage in the IRI model.…”

Section: Clinical Trials Of Mscs Therapy In Kdmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges

Chen

Xia

et al. 2023

Cell Transplant

View full text Add to dashboard Cite

Kidney disease (KD) is a life-threatening disease characterized by high morbidity and mortality in clinical settings, which can be caused by many reasons, and the incidence increases with age. However, supportive therapy and kidney transplantation still have limitations in alleviating KD progression. Recently, mesenchymal stem cells (MSCs) have shown great potential in repairing injury through their multidirectional differentiation and self-renewal ability. Of note, MSCs serve as a safe and effective therapeutic strategy for treating KD in preclinical and clinical trials. Functionally, MSCs ameliorate KD progression by regulating the immune response, renal tubular cell apoptosis, tubular epithelial–mesenchymal transition, oxidative stress, angiogenesis, and so on. In addition, MSCs exhibit remarkable efficacy in both acute kidney injury (AKI) and chronic kidney disease (CKD) through paracrine mechanisms. In this review, we outline the biological characteristics of MSCs, discuss the efficacy and mechanisms of MSCs-based therapy for KD, summarize the completed and ongoing clinical trials, as well as analyze limitations and new strategies, aiming to provide new ideas and approaches for the preclinical experiments and clinical trials of MSCs transplantation for KD.

show abstract

Section: Clinical Trials Of Mscs Therapy In Kdmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges

Chen

Xia

et al. 2023

Cell Transplant

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that EVs secreted by MSCs have similar therapeutic effects on MSCs because some of the paracrine effects of MSCs are derived from exosomes, and most of the therapeutic effects of MSCs are responsible for the paracrine effects of EVs in certain diseases via miRNAs, mRNAs, and proteins as functional molecules [ 212 , 213 , 214 , 215 ].…”

Section: Therapy Via Msc-derived Evs As a Novel Dds Systemmentioning

confidence: 99%

Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine

Matsuzaka

Yashiro

2022

IJMS

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are lipid bilayer membrane particles that play critical roles in intracellular communication through EV-encapsulated informative content, including proteins, lipids, and nucleic acids. Mesenchymal stem cells (MSCs) are pluripotent stem cells with self-renewal ability derived from bone marrow, fat, umbilical cord, menstruation blood, pulp, etc., which they use to induce tissue regeneration by their direct recruitment into injured tissues, including the heart, liver, lung, kidney, etc., or secreting factors, such as vascular endothelial growth factor or insulin-like growth factor. Recently, MSC-derived EVs have been shown to have regenerative effects against various diseases, partially due to the post-transcriptional regulation of target genes by miRNAs. Furthermore, EVs have garnered attention as novel drug delivery systems, because they can specially encapsulate various target molecules. In this review, we summarize the regenerative effects and molecular mechanisms of MSC-derived EVs.

show abstract

“…Moreover, stem cells may have potential carcinogenicity, which greatly limits their clinical applications (Hickson et al, 2016). Emerging evidence confirms that MSC-exosomes can be used as natural carriers for targeted drug delivery (Cao et al, 2022). Thus, therapeutic agents can be efficiently incorporated into exosomes and then delivered to diseased tissues.…”

Section: Stem Cellsmentioning

confidence: 99%

The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome

Yao

Liu²,

Sun³

et al. 2022

Front. Physiol.

View full text Add to dashboard Cite

Cardiorenal syndrome (CRS) is defined as a disorder of the heart and kidney, in which acute or chronic injury of one organ may lead to acute or chronic dysfunction of the other. It is characterized by high morbidity and mortality, resulting in high economic costs and social burdens. However, there is currently no effective drug-based treatment. Emerging evidence implicates the involvement of mitophagy in the progression of CRS, including cardiovascular disease (CVD) and chronic kidney disease (CKD). In this review, we summarized the crucial roles and molecular mechanisms of mitophagy in the pathophysiology of CRS. It has been reported that mitophagy impairment contributes to a vicious loop between CKD and CVD, which ultimately accelerates the progression of CRS. Further, recent studies revealed that targeting mitophagy may serve as a promising therapeutic approach for CRS, including clinical drugs, stem cells and small molecule agents. Therefore, studies focusing on mitophagy may benefit for expanding innovative basic research, clinical trials, and therapeutic strategies for CRS.

show abstract

Mesenchymal Stem Cell-Derived Exosomes: Toward Cell-Free Therapeutic Strategies in Chronic Kidney Disease

Cited by 20 publications

References 138 publications

Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges

Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges

Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine

The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome

Contact Info

Product

Resources

About